Predictive value of immune parameters before treatment interruption (TI) for CD1+ T-cell count change during TI in HIV infection

Antiviral Therapy

Volumn 14, Issue 3, 2009, Pages 381-392

  Huang, Kenneth H ^a   Loutfy, Mona R ^b   Boulet, Salix ^a   Toma, Emil ^c   Tsoukas, Christos M ^a   Bernard, Nicole F ^a  

^a MCGILL UNIVERSITY HEALTH CENTRE   (Canada)

^b UNIVERSITY OF TORONTO   (Canada)

^c UNIVERSITÉ DE MONTRÉAL   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIRETROVIRUS AGENT; CD28 ANTIGEN; CD57 ANTIGEN; CELL MARKER; GAG PROTEIN; PROTEIN P55;

ADULT; ANTIGEN EXPRESSION; ARTICLE; CD28 T LYMPHOCYTE; CD4 LYMPHOCYTE COUNT; CD4+ CD8+ T LYMPHOCYTE PERCENTAGE; CD57 T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CLINICAL ARTICLE; COMBINATION CHEMOTHERAPY; CONTROLLED STUDY; DRUG WITHDRAWAL; HUMAN; HUMAN CELL; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IMMUNOLOGICAL PARAMETERS; LYMPHOCYTE PROLIFERATION; PERIPHERAL BLOOD MONONUCLEAR CELL; PRIORITY JOURNAL; T LYMPHOCYTE; TREATMENT INTERRUPTION; VIRUS LOAD;

ADULT; ANTIGENS, CD28; ANTIGENS, CD57; BIOLOGICAL MARKERS; CD4 LYMPHOCYTE COUNT; CD4-POSITIVE T-LYMPHOCYTES; CD8-POSITIVE T-LYMPHOCYTES; CELL PROLIFERATION; CELLS, CULTURED; CHRONIC DISEASE; HIV INFECTIONS; HUMANS; PREDICTIVE VALUE OF TESTS; RETROSPECTIVE STUDIES; VIRAL LOAD;

EID: 67649188411     PISSN: 13596535     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (49)

1. Palella FJ, Jr, Delaney KM, Moorman AC, et al. Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection. N Engl J Med 1998; 338:853-860.
2. Phillips AN, Staszewski S, Lampe F, et al. Human immunodeficiency virus rebound after suppression to <400 copies/ml during initial highly active antiretroviral therapy regimens, according to prior nucleoside experience and duration of suppression. J Infect Dis 2002; 186:1086-1091.
3. Mocroft A, Phillips AN, Friis-Moller N, et al. Response to antiretroviral therapy among patients exposed to three classes of antiretrovirals: results from the EuroSIDA study. Antivir Ther 2002; 7:21-30.
4. Pai NP, Talsky JP, Lawrence J, Colford JM, Jr, Reingold AL. Structured treatment interruptions (STI) in chronic suppressed HIV infection in adults. Cochrane Database Syst Rev 2005; 4:CD005482.
5. Walmsley S, Loutfy M. Can structured treatment interruptions (STIs) be used as a strategy to decrease total drug requirements and toxicity in HIV infection? J Int Assoc Physicians AIDS Care (Chic Ill) 2002; 1:95-103.
6. Tuldra A, Fumaz CR, Ferrer MJ, et al. Psychological impact of structured treatment interruptions in patients with prolonged undetectable HIV-1 viral loads. AIDS 2001; 15:1904-1906.
7. Lori F, Lewis MG, Xu J, et al. Control of SIV rebound through structured treatment interruptions during early infection. Science 2000; 290:1591-1593.
8. Rosenberg ES, Altfeld M, Poon SH, et al. Immune control of HIV-1 after early treatment of acute infection. Nature 2000; 407:523-526.
9. Kaufmann DE, Lichterfeld M, Altfeld M, et al. Limited durability of viral control following treated acute HIV infection. PLoS Med 2004; 1:e36.
10. Katlama C, Dominguez S, Gourlain K, et al. Benefit of treatment interruption in HIV-infected patients with multiple therapeutic failures: a randomized controlled trial (ANRS 097). AIDS 2004; 18:217-226.
11. Lawrence J, Mayers DL, Hullsiek KH, et al. Structured treatment interruption in patients with multidrug-resistant human immunodeficiency virus. N Engl J Med 2003; 349:837-846.
12. Lawrence J, Hullsiek KH, Thackeray LM, et al. Disadvantages of structured treatment interruption persist in patients with multidrug-resistant HIV-1: final results of the CPCRA 064 study. J Acquir Immune Defic Syndr 2006; 43:169-178.
13. Ananworanich J, Gayet-Ageron A, Le Braz M, et al. CD4-guided scheduled treatment interruptions compared with continuous therapy for patients infected with HIV-1: results of the Staccato randomised trial. Lancet 2006; 368:459-465.
14. Marchou B, Tangre P, Charreau I, et al. Intermittent antiretroviral therapy in patients with controlled HIV infection. AIDS 2007; 21:457-466.
15. + cell-count-guided treatment interruptions in chronic HIV-infected patients with good response to highly active antiretroviral therapy. AIDS 2004; 18:2381-2389.
16. Danel C, Moh R, Minga A, et al. CD4-guided structured antiretroviral treatment interruption strategy in HIV-infected adults in west Africa (Trivacan ANRS 1269 trial): a randomised trial. Lancet 2006; 367:1981-1989.
17. + count-guided interruption of antiretroviral treatment. N Engl J Med 2006; 355:2283-2296.
18. Ruiz L, Paredes R, Gomez G, et al. Antiretroviral therapy interruption guided by CD4 cell counts and plasma HIV-1 RNA levels in chronically HIV-1-infected patients. AIDS 2007; 21:169-178.
19. Dart Trial Team. Fixed duration interruptions are inferior to continuous treatment in African adults starting therapy with CD4 cell counts < 200 cells/microl. AIDS 2008; 22:237-247.
20. Touloumi G, Pantazis N, Antoniou A, Stirnadel HA, Walker SA, Porter K. High active antiretroviral therapy interruption: predictors and virological and immunologic consequences.J Acquir Immune Defic Syndr 2006; 42:554-561.
21. Holkmann Olsen C, Mocroft A, Kirk O, et al. Interruption of combination antiretroviral therapy and risk of clinical disease progression to AIDS or death. HIV Med 2007; 8:96-104.
22. Deeks SG, Wrin T, Liegler T, et al. Virologic and immunologic onsequences of discontinuing combination antiretroviral-drug therapy in HIV-infected patients with detectable viremia. N Engl J Med 2001; 344:472-480.
23. + T cell proliferation is coupled to perform expression and is maintained in nonprogressors. Nat Immunol 2002; 3:1061-1068.
24. + T cells endowed with proliferative capacity. J Exp Med 2003; 198:1909-1922.
25. Gamberg J, Pardoe I, Bowmer MI, Howley C, Grant M. Lack of CD28 expression on HIV-specific cytotoxic T lymphocytes is associated with disease progression. Immunol Cell Biol 2004; 82:38-46.
26. + T lymphocytes during HIV-1 infection. J Acquir Immune Defic Syndr 1994; 7:245-253.
27. Hatzakis G, Tsoukas C. Neural networks in the assessment of HIV immunopathology. Proc AMIA Symp 2001:249-253.
28. + T cells. Blood 2003; 101:2711-2720.
29. + T cells and their association with HIV-1 induced T cell dysfunction. J Immunol 2005; 175:8415-8423.
30. Skiest DJ, Su Z, Havlir DV, et al. Interruption of antiretroviral treatment in HIV-infected patients with preserved immune function is associated with a low rate of clinical progression: a prospective study by AIDS Clinical Trials Group 5170. J Infect Dis 2007; 195:1426-1436.
31. + T cells is an independent predictor of high mortality in human immunodeficiency virus type 1-infected patients. J Infect Dis 2003; 187:1726-1734.
32. Rudd CE. Upstream-downstream: CD28 cosignaling pathways and T cell function. Immunity 1996; 4:527-534.
33. -T cells. AIDS 1994; 8:431-441.
34. Giorgi JV, Hultin LE, McKeating JA, et al. Shorter survival in advanced human immunodeficiency virus type 1 infection is more closely associated with T lymphocyte activation than with plasma virus burden or virus chemokine coreceptor usage. J Infect Dis 1999; 179:859-870.
35. + T cell count in HIV-seropositive individuals with undetectable plasma HIV RNA levels in the absence of therapy. J Infect Dis 2008; 197:126-133.
36. 8 T cells specific for EBV, cytomegalovirus, and influenza virus are activated during primary HIV infection. J Immunol 2004; 173:2410-2418.
37. Schrier RD, Wiley CA, Spina C, McCutchan JA, Grant I. Pathogenic and protective correlates of T cell proliferation in AIDS. HNRC Group. HIV Neurobehavioral Research Center. J Clin Invest 1996; 98:731-740.
38. + T-cell differentiation towards senescence in HIV-1 nfection. PLoS Biol 2004; 2:e20.
39. + T cell proliferative ability but not loss of human immunodeficiency virus type 1 specificity equates with progression to disease. J Infect Dis 2000;182:792-798.
40. + T-cell responses to different HIV proteins have discordant associations with viral load. Nat Med 2007; 13:46-51.
41. + cell numbers and clinical staging. J Clin Invest 1989; 84:1892-1899.
42. Rinaldo CR, Jr., Liebmann JM, Huang XL, et al. Prolonged suppression of human immunodeficiency virus type 1 (HIV-1) viremia in persons with advanced disease results in enhancement of CD4 T cell reactivity to microbial antigens but not to HIV-1 antigens. J Infect Dis 1999; 179:329-336.
43. Al-Harthi L, Siegel J, Spritzler J, Pottage J, Agnoli M, Landay A. Maximum suppression of HIV replication leads to the restoration of HIV-specific responses in early HIV disease. AIDS 2000; 14:761-770.
44. Appay V, Rowland-Jones SL. Premature ageing of the immune system: the cause of AIDS? Trends Immunol 2002; 23:580-585.
45. Appay V, Almeida JR, Sauce D, Autran B, Papagno L. Accelerated immune senescence and HIV-1 infection. Exp Gerontol 2007; 42:432-437.
46. Appay V, Sauce D. Immune activation and inflammation in HIV-1 infection: causes and consequences. J Pathol 2008; 214:231-241.
47. Koch S, Larbi A, Ozcelik D, et al. Cytomegalovirus infection: a driving force in human T cell immunosenescence. Ann NY Acad Sci 2007; 1114:23-35.
48. Poulton MB, Sabin CA, Fisher M. Immunological changes during treatment interruptions: risk factors and clinical sequelae. AIDS 2003; 17:126-128.
49. Huang KH, Loutfy MR, Tsoukas CM, Bernard NF. Immune correlates of CD4 decline in HIV-infected patients experiencing virologic failure before undergoing treatment interruption. BMC Infect Dis 2008; 8:59.